About USTMA

Drs. Mazepa and Cataland formed the United States Thrombotic Microangiopathy (USTMA) Consortium in 2014 as a grassroots effort to organize research efforts in the thrombotic microangiopathies. The US Thrombotic Microangiopathy Alliance, a 501(c)(3) non-profit organization with the EIN 83-1768842, is committed to fostering collaboration and forming a true alliance with other advocacy organizations. Recognizing the importance of collective efforts in making a meaningful impact, the alliance actively seeks partnerships with like-minded organizations dedicated to improving the lives of individuals affected by thrombotic microangiopathy (TMA) in the United States. By joining forces, sharing resources, and pooling expertise, the US Thrombotic Microangiopathy Alliance aims to create a stronger, united front in raising awareness, advocating for improved care and treatment options, and supporting vital research initiatives. Together with their partners, the alliance strives to enhance the reach and effectiveness of their advocacy efforts, bringing about positive change and improved outcomes for the TMA community.

The USTMA now incorporates 15 large US referral centers with:

• A large referral base of patients with TMAs.

• A minimum of 1 site leader with a career interest in clinical/translational research in TMA.

• Adequate clinical/translational research facilities and resources to participate in these research activities.

Due to the limited access to research funds the USTMA is unable to provide indirect costs for studies.